Stratification of Length of Stay Prediction following Surgical Cytoreduction in Advanced High-Grade Serous Ovarian Cancer Patients Using Artificial Intelligence; the Leeds L-AI-OS Score.

artificial intelligence deep learning epithelial ovarian cancer graphical user interface length of stay machine learning surgical cytoreduction

Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
23 11 2022
Historique:
received: 09 10 2022
revised: 11 11 2022
accepted: 21 11 2022
entrez: 22 12 2022
pubmed: 23 12 2022
medline: 27 12 2022
Statut: epublish

Résumé

(1) Background: Length of stay (LOS) has been suggested as a marker of the effectiveness of short-term care. Artificial Intelligence (AI) technologies could help monitor hospital stays. We developed an AI-based novel predictive LOS score for advanced-stage high-grade serous ovarian cancer (HGSOC) patients following cytoreductive surgery and refined factors significantly affecting LOS. (2) Methods: Machine learning and deep learning methods using artificial neural networks (ANN) were used together with conventional logistic regression to predict continuous and binary LOS outcomes for HGSOC patients. The models were evaluated in a post-hoc internal validation set and a Graphical User Interface (GUI) was developed to demonstrate the clinical feasibility of sophisticated LOS predictions. (3) Results: For binary LOS predictions at differential time points, the accuracy ranged between 70-98%. Feature selection identified surgical complexity, pre-surgery albumin, blood loss, operative time, bowel resection with stoma formation, and severe postoperative complications (CD3-5) as independent LOS predictors. For the GUI numerical LOS score, the ANN model was a good estimator for the standard deviation of the LOS distribution by ± two days. (4) Conclusions: We demonstrated the development and application of both quantitative and qualitative AI models to predict LOS in advanced-stage EOC patients following their cytoreduction. Accurate identification of potentially modifiable factors delaying hospital discharge can further inform services performing root cause analysis of LOS.

Identifiants

pubmed: 36547125
pii: curroncol29120711
doi: 10.3390/curroncol29120711
pmc: PMC9776955
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9088-9104

Références

Cancer Control. 2021 Jan-Dec;28:10732748211044678
pubmed: 34693730
J Am Coll Surg. 2016 Aug;223(2):259-270.e2
pubmed: 27188832
Obstet Gynecol. 2001 May;97(5 Pt 1):721-4
pubmed: 11339923
J Ovarian Res. 2020 Sep 29;13(1):117
pubmed: 32993745
Med Care. 2015 Apr;53(4):355-65
pubmed: 25769056
World J Surg. 2018 Dec;42(12):3888-3896
pubmed: 29978247
J Clin Med. 2021 Dec 24;11(1):
pubmed: 35011828
Int J Surg. 2016 Dec;36(Pt A):121-126
pubmed: 27780772
J Pers Med. 2022 Apr 10;12(4):
pubmed: 35455723
Br J Surg. 2018 Nov;105(12):1680-1687
pubmed: 29974946
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003288
pubmed: 19370584
Int J Gynecol Cancer. 2015 Jan;25(1):55-62
pubmed: 25427238
J Clin Oncol. 2003 Mar 15;21(6):1133-8
pubmed: 12637481
Eur J Surg Oncol. 2018 Jul;44(7):969-974
pubmed: 29784507
Chest. 1999 Aug;116(2):355-62
pubmed: 10453862
J Hosp Infect. 2017 May;96(1):1-15
pubmed: 28410761
Am J Surg. 2016 May;211(5):954-7
pubmed: 27046795
Am J Obstet Gynecol. 2007 Dec;197(6):676.e1-7
pubmed: 18060979
Cochrane Database Syst Rev. 2022 Feb 24;2:CD000313
pubmed: 35199849
Arch Surg. 2007 May;142(5):461-5; discussion 465-6
pubmed: 17515488
Arch Surg. 1999 Jan;134(1):36-42
pubmed: 9927128
Gynecol Oncol. 2007 Oct;107(1):99-106
pubmed: 17602726
Eur J Cancer. 2016 May;59:22-33
pubmed: 26998845
Clin Nutr. 2017 Oct;36(5):1187-1196
pubmed: 28689670
Transl Cancer Res. 2022 Oct;11(10):3853-3868
pubmed: 36388027
Arch Gynecol Obstet. 2011 Aug;284(2):445-51
pubmed: 20803205
Health Inf Sci Syst. 2020 Feb 01;8(1):9
pubmed: 32071714
Br J Surg. 2015 Feb;102(3):269-80
pubmed: 25524216
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Medicine (Baltimore). 2016 Nov;95(47):e5064
pubmed: 27893655
Br J Surg. 2010 May;97(5):772-81
pubmed: 20306528
Artif Intell Med. 2007 Jul;40(3):211-21
pubmed: 17580112
Gynecol Oncol. 2006 Dec;103(3):1048-53
pubmed: 16876237
J Health Serv Res Policy. 2016 Apr;21(2):91-100
pubmed: 26811374
Healthcare (Basel). 2019 Jul 03;7(3):
pubmed: 31277282
BMC Cancer. 2010 May 25;10:232
pubmed: 20497581
J Med Internet Res. 2016 Dec 16;18(12):e323
pubmed: 27986644
PLoS One. 2016 Oct 25;11(10):e0165315
pubmed: 27780274
Br J Nutr. 2015 Nov 28;114(10):1612-22
pubmed: 26369948
Colorectal Dis. 2012 Oct;14(10):e727-34
pubmed: 22594524
Gynecol Oncol. 2015 Jan;136(1):65-70
pubmed: 25451693
Cochrane Database Syst Rev. 2011 Feb 16;(2):CD007635
pubmed: 21328298
World J Gastroenterol. 2009 Jul 28;15(28):3542-9
pubmed: 19630112
Surgery. 2005 Nov;138(5):837-43
pubmed: 16291383
J Oncol Pract. 2018 Dec;14(12):e823-e833
pubmed: 30537462
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Sci Rep. 2020 Jul 30;10(1):12818
pubmed: 32733086
Gynecol Oncol. 2012 May;125(2):336-42
pubmed: 22261299
Cancers (Basel). 2022 Jul 15;14(14):
pubmed: 35884506
Eur J Cancer. 2020 Sep;136:149-158
pubmed: 32688208
J Am Med Inform Assoc. 2018 Sep 1;25(9):1259-1265
pubmed: 29718258
Gynecol Oncol. 2018 Aug;150(2):306-310
pubmed: 29929924
J Am Coll Surg. 2004 Apr;198(4):626-32
pubmed: 15051016

Auteurs

Alexandros Laios (A)

ESGO Centre of Excellence for Ovarian Cancer Surgery, Department of Gynaecological Oncology, St James's University Hospital, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.

Daniel Lucas Dantas De Freitas (DLD)

Department of Chemistry, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil.

Gwendolyn Saalmink (G)

ESGO Centre of Excellence for Ovarian Cancer Surgery, Department of Gynaecological Oncology, St James's University Hospital, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.

Yong Sheng Tan (YS)

ESGO Centre of Excellence for Ovarian Cancer Surgery, Department of Gynaecological Oncology, St James's University Hospital, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.

Racheal Johnson (R)

ESGO Centre of Excellence for Ovarian Cancer Surgery, Department of Gynaecological Oncology, St James's University Hospital, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.

Albina Zubayraeva (A)

ESGO Centre of Excellence for Ovarian Cancer Surgery, Department of Gynaecological Oncology, St James's University Hospital, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.

Sarika Munot (S)

ESGO Centre of Excellence for Ovarian Cancer Surgery, Department of Gynaecological Oncology, St James's University Hospital, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.

Richard Hutson (R)

ESGO Centre of Excellence for Ovarian Cancer Surgery, Department of Gynaecological Oncology, St James's University Hospital, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.

Amudha Thangavelu (A)

ESGO Centre of Excellence for Ovarian Cancer Surgery, Department of Gynaecological Oncology, St James's University Hospital, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.

Tim Broadhead (T)

ESGO Centre of Excellence for Ovarian Cancer Surgery, Department of Gynaecological Oncology, St James's University Hospital, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.

David Nugent (D)

ESGO Centre of Excellence for Ovarian Cancer Surgery, Department of Gynaecological Oncology, St James's University Hospital, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.

Evangelos Kalampokis (E)

Information Systems Lab., Department of Business Administration, University of Macedonia, 54636 Thessaloniki, Greece.
Center for Research & Technology HELLAS (CERTH), 6th km Charilaou-Thermi Rd., 57001 Thessaloniki, Greece.

Kassio Michell Gomes de Lima (KMG)

Department of Chemistry, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil.

Georgios Theophilou (G)

ESGO Centre of Excellence for Ovarian Cancer Surgery, Department of Gynaecological Oncology, St James's University Hospital, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.

Diederick De Jong (D)

ESGO Centre of Excellence for Ovarian Cancer Surgery, Department of Gynaecological Oncology, St James's University Hospital, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH